“Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns: Original scientific article” (2025) ADMET and DMPK, 13(5), p. 2956. doi:10.5599/admet.2956.